Overview

* Prestige Consumer's Q1 rev drops to $249.5 mln, missing analysts' expectations

* Diluted EPS for fiscal Q1 rises 6% yr/yr to $0.95

* Co to acquire Pillar5 Pharma, addressing eye care supply chain issues

Outlook

* Prestige lowers fiscal 2026 revenue outlook to $1,100 to $1,115 mln

* Company now anticipates fiscal 2026 EPS of $4.50 to $4.58

* Prestige expects eye care supply improvements in second half of fiscal 2026

* Company maintains fiscal 2026 free cash flow forecast of $245 mln or more

Result Drivers

* SUPPLY CONSTRAINTS - Revenue decline attributed to limited ability to supply of Clear Eyes products

* INTERNATIONAL GROWTH - Strong growth in international OTC segment partially offset revenue decline

* ACQUISITION STRATEGY - Acquisition of Pillar5 Pharma aimed at improving eye care supply chain

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss $249.53 $261 mln

Revenue mln (6

Analysts

)

Q1 Net $47.47

Income mln

Q1 Gross $140.33

Profit mln

Q1 $68.58

Operatin mln

g

Expenses

Q1 $71.76

Operatin mln

g Income

Q1 $61.78

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc ( PBH ) is $90.00, about 16.5% above its August 6 closing price of $75.16

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)